Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
RAPT Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
RAPT Therapeutics's earnings have been declining at an average annual rate of -23.2%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 16.2% per year.
Anahtar bilgiler
-23.2%
Kazanç büyüme oranı
68.2%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | -16.2% |
Özkaynak getirisi | -110.3% |
Net Marj | n/a |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Jul 24Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
May 20Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study
Jun 14RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth
Feb 15RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year
Jan 18RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction
Jan 08Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like
Dec 21The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares
Nov 23Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 19RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers
Nov 16Gelir ve Gider Dağılımı
RAPT Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 0 | -120 | 28 | 101 |
31 Mar 24 | 0 | -118 | 28 | 100 |
31 Dec 23 | 0 | -117 | 26 | 101 |
30 Sep 23 | 0 | -109 | 25 | 94 |
30 Jun 23 | 0 | -99 | 23 | 83 |
31 Mar 23 | 1 | -93 | 21 | 76 |
31 Dec 22 | 2 | -84 | 20 | 67 |
30 Sep 22 | 2 | -79 | 20 | 62 |
30 Jun 22 | 3 | -76 | 18 | 61 |
31 Mar 22 | 3 | -73 | 17 | 60 |
31 Dec 21 | 4 | -69 | 16 | 57 |
30 Sep 21 | 4 | -64 | 15 | 54 |
30 Jun 21 | 5 | -60 | 14 | 51 |
31 Mar 21 | 5 | -56 | 13 | 49 |
31 Dec 20 | 5 | -53 | 13 | 45 |
30 Sep 20 | 4 | -53 | 12 | 45 |
30 Jun 20 | 2 | -49 | 10 | 40 |
31 Mar 20 | 1 | -47 | 10 | 38 |
31 Dec 19 | 0 | -43 | 9 | 35 |
30 Sep 19 | 0 | -39 | 7 | 33 |
30 Jun 19 | 0 | -40 | 7 | 34 |
31 Mar 19 | 0 | -37 | 6 | 32 |
31 Dec 18 | 0 | -36 | 5 | 32 |
Kaliteli Kazançlar: RAPT is currently unprofitable.
Büyüyen Kar Marjı: RAPT is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: RAPT is unprofitable, and losses have increased over the past 5 years at a rate of 23.2% per year.
Büyüme Hızlandırma: Unable to compare RAPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: RAPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Özkaynak Getirisi
Yüksek ROE: RAPT has a negative Return on Equity (-110.26%), as it is currently unprofitable.